Cancer Center, Renmin Hospital of Wuhan University, 99 Zhangzhidong Road, Wuchang District, Wuhan, 430060, Hubei Province, China.
Department of Neurosurgery, Renmin Hospital of Wuhan University, 99 Zhangzhidong Road, Wuchang District, Wuhan, 430060, Hubei Province, China.
BMC Cancer. 2022 May 6;22(1):498. doi: 10.1186/s12885-022-09595-0.
Tubulin alpha-1c chain (TUBA1C), a subtype of α-tubulin, has been shown to be involved in cell proliferation and cell cycle progression in several cancers and to influence cancer development and prognosis. However, a pancancer analysis of TUBA1C to reveal its immunological and prognostic roles has not been performed. In this study, we first downloaded raw data on TUBA1C expression in cancers from The Cancer Genome Atlas (TCGA) database and multiple other databases and analysed these data with R software to investigate the prognostic and immunological value of TUBA1C in cancers. Immunohistochemical analysis was performed in gliomas to further validate our findings. Overall, TUBA1C was overexpressed in most cancers, and overexpression of TUBA1C was linked to poor prognosis and higher tumour grade in patients. In addition, TUBA1C expression was associated with tumour mutation burden (TMB), microsatellite instability (MSI), the tumour microenvironment (TME) and the infiltration of immune cells. TUBA1C was also coexpressed with most immune-related genes and influenced immune-related pathways. Immunohistochemical analysis showed that TUBA1C expression was highest in glioblastoma (GBM) tissues, second highest in low-grade glioma (LGG) tissues and lowest in normal tissues. Our study indicated that TUBA1C might be a biomarker for predicting the immune status and prognosis of cancers, offering new ideas for cancer treatment.
微管蛋白 α-1c 链(TUBA1C)是α-微管蛋白的一种亚型,已被证明参与了几种癌症中的细胞增殖和细胞周期进程,并影响癌症的发展和预后。然而,尚未对 TUBA1C 进行泛癌症分析以揭示其免疫和预后作用。在这项研究中,我们首先从癌症基因组图谱(TCGA)数据库和多个其他数据库中下载了 TUBA1C 表达的原始数据,并使用 R 软件对这些数据进行了分析,以研究 TUBA1C 在癌症中的预后和免疫价值。我们还对胶质瘤进行了免疫组织化学分析,以进一步验证我们的发现。总的来说,TUBA1C 在大多数癌症中过表达,并且 TUBA1C 的过表达与患者的预后不良和肿瘤分级较高相关。此外,TUBA1C 的表达与肿瘤突变负担(TMB)、微卫星不稳定性(MSI)、肿瘤微环境(TME)和免疫细胞浸润有关。TUBA1C 还与大多数免疫相关基因共表达,并影响免疫相关途径。免疫组织化学分析表明,TUBA1C 在胶质母细胞瘤(GBM)组织中的表达最高,在低级别胶质瘤(LGG)组织中的表达次之,在正常组织中的表达最低。我们的研究表明,TUBA1C 可能是预测癌症免疫状态和预后的生物标志物,为癌症治疗提供了新的思路。